Premium Information is available for this item - Upgrade for $1 a day
6505-00-066-4875
Usp Liothyronine Sodium Tablets
6505000664875 000664875 CYTOMEL NDC00007-3416-30
November 2023
18
Marketplace 6505-00-066-4875
Request a Quotation from participating marketplace vendors
Related Documents 6505-00-066-4875 5+ Documents (More...)
Usp Liothyronine Sodium Tablets 000664875 Upgrade your Account Upgrade 6505-00-066-4875Usp Liothyronine
Sodium Tablets6505000664875 000664875 CYTOMEL NumberManufacturerStatusNDC00007-3416-30 93544 - Glaxosmithkline
006601609 Stock Numbers Related to 6505-00-660-1609 6505-00-066-4875 6505-27-000-6216 Control Point,
Neg Radical NATO Stock Numbers Related to 6505-00-066-4875 6505-00-066-4875 6505-27-000-6216 MechanicsburgSpecial
Usp Liothyronine Sodium Tablets 000664875 Neg Radical NATO Stock Numbers Related to 6505-00-066
-4875 6505-00-066-4875 6505-27-000-6216 6505-00-660-1609 Restrictions 6505-00-660-1609 DEMIL: A | DEMILI
Restrictions 6505-00-066-4875
6505-00-066-4875 is a Usp Liothyronine Sodium Tablets that does not have a nuclear hardened feature or any other critical feature such as tolerance, fit restriction or application. Demilitarization of this item has been confirmed and is not currently subject to changes. This item is considered a low risk when released from the control of the Department of Defense. The item may still be subject to the requirements of the Export Administration Regulations (EAR) and the Code of Federal Regulations (CFR). This item may be hazardous as it is in a Federal Supply Class for potentially hazardous items. A MSDS should be available from the supplier for the end user to evaluate any hazards. This item does not contain a precious metal.
End Users 6505-00-066-4875
- NASA (G57V)
- Effective Date:
- 1 Apr 1991
- Kuwait (YK01)
- Effective Date:
- 1 Jan 2015
Approved Sources 6505-00-066-4875
- Part Number
- Manufacturer
- Status
- NDC00007-3416-30
- Manufacturer
- 93544 - Glaxosmithkline Holdings (Americas) (Obsolete)
- Primary Buy
- Primary Buy
- CYTOMEL
- 93544 - Glaxosmithkline Holdings (Americas) (Obsolete)
- Incomplete Secondary Reference
- Incomplete Secondary Reference
Datasheet 6505-00-066-4875
- Characteristic
- Specifications
- Administration [CSGS]
- Specifications
- Oral
- Primary Container Type [CQCT]
- Bottle
- Primary Container Content Quantity [CRLK]
- 1000.000 Tablets
- Features Provided [CBBL]
- Enteric Coated
- Special Features [FEAT]
- Tablet Hardness Shall Be Not Less Than 7 When Determined On A Strong-Cobb Hardness Tester;Active Medicament Medicinal Strength:25.000 Ug Liothyronine Active Ingredient Equivalant Of Neg Radical
NATO Stock Numbers Related to 6505-00-066-4875
Freight Information 6505-00-066-4875
6505-00-066-4875 has freight characteristics.It has a National Motor Freight Classification (NMFC) of 058770. A Sub NMFC of Z. It has a NMFC Description of DRUGS/MEDICINES/VITAMINS NOI. 6505-00-066-4875 is rated as a variable freight class when transported by Less-Than Truckload (LTL) freight. It has a Uniform Freight Classification (UFC) number of 33400 which rates the freight between FCL and LCL. 6505-00-066-4875 has a variance between NMFC and UFC when transported by rail and the description should be consulted. It has a Water Commodity Code (WCC) of 532 for ocean manifesting and military sealift. 6505-00-066-4875 is not classified as a special type of cargo when transported by water. 6505-00-066-4875 is not a consolidation and does not exceed 84" in any dimension. It should be compatible with a standard 72" Aircraft Cargo Door when transported by air.